AbbVie reaches deal that guarantees monopoly pricing for the next five years for Humira

AbbVie reached a deal with biopharmaceutical firm Samsung Bioepis that prevents Samsung from selling its cheaper copy of blockbuster drug Humira in the United States until June 30, 2023.   This settlement guarantees monopoly pricing for the next five years; however, even though biosimilar versions of Humira will be available in Europe this October. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.